A phase 2 randomized trial of apremilast in patients with atopic dermatitis
Journal of Investigative Dermatology Dec 10, 2018
Simpson E, et al. - Experts conducted a phase 2, double-blind, placebo-controlled trial to assess the apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopic dermatitis (AD). They randomized the patients to placebo, apremilast 30 mg BID (APR30), or apremilast 40 mg BID (APR40) for 12 weeks. In moderate to severe AD patients, modest efficacy and decreased AD-related biomarkers was demonstrated by APR40. They noted adverse events (AEs), including cellulitis, more frequently with APR40, which was discontinued during the trial. With apremilast’s known profile, safety with APR30 was largely consistent.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries